Republic of Korea
Tuberculosis profile
Population  2012 49 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.6 (0.16–8.5) 5.4 (0.32–17)
Mortality (HIV+TB only) 0.024 (0.019–0.028) 0.05 (0.04–0.06)
Prevalence  (includes HIV+TB) 71 (58–86) 146 (119–175)
Incidence  (includes HIV+TB) 53 (46–60) 108 (95–122)
Incidence (HIV+TB only) 0.15 (0.13–0.17) 0.31 (0.27–0.35)
Case detection, all forms (%) 82 (73–94)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 12 137 (31) Relapse 4 157 (42)
Smear-negative 15 622 (40) Treatment after failure 102 (1)
Smear-unknown / not done 3 316 (8) Treatment after default 699 (7)
Extrapulmonary 8 470 (21) Other 5 029 (50)
Other 0 (0)      
Total new 39 545   Total retreatment 9 987  
           
Other (history unknown) 0        
Total new and relapse 43 702   Total cases notified 49 532  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.5 1.5 1.0
Age < 15 33 170 97
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 51.0
Drug susceptibility testing (per 5 million population) 0.7
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 80   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 82  
Retreatment 74  
TB/HIV 2012 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.7 (2.1–3.4) 14 (10–19)
MDR-TB cases among notified pulmonary
TB cases
840 (660–1 100) 1 400 (1 000–1 900)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     1 212
Patients started on MDR-TB treatment     1 212
Financing TB control 2013
National TB programme budget (US$ millions) 22
% Funded domestically  
% Funded internationally  
% Unfunded 100%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data